# A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome

> **NCT05307679** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 7 (actual)

## Conditions studied

- Dup15q Syndrome

## Interventions

- **DRUG:** Basmisanil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05307679
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-16
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was terminated due to sponsor decision and not related to safety or tolerability.
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307679, "A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05307679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*